Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy

Fabio Da Roit,1* Patrick J. Engelberts,2* Ronald P. Taylor,3 Esther C.W. Breij,2 Giuseppe Gritti,1 Alessandro Rambaldi,1 Martino Introna,1 Paul W.H.I. Parren,2,4 Frank J. Beurskens,2 and Josée Golay1

1Center of Cellular Therapy “G. Lanzani”, Division of Hematology, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; 2Genmab, Utrecht, the Netherlands; 3Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, VA, USA; and 4Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark

*FDR and PJE contributed equally to this work.

©2014 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2014.107011
Manuscript received on March 10, 2014. Manuscript accepted on October 20, 2014.
Correspondence: jgolay@hpg23.it
Supplementary Figure 1. Effect of ibrutinib alone on MEC-1 and BJAB. Cells were plated in presence or absence of 0.1 to 10 µM ibrutinib. Absolute numbers of live cells were measured at 30 and 72 hours by flow cytometry, using 7-AAD and calibration beads.
Supplementary Figure 2. Dot plot of degranulation of NK cells by flow cytometry. PBMC were untreated or treated for 1 hour with 0.1, 1 or 10 µM ibrutinib followed by 4 hours incubation with CLL (CTRL) or CLL opsonised with OBZ. Percentages of CD107a⁺ CD56⁺ NK cells are shown in each panel.
Supplementary Fig. 3. Results of ADCC assays of MEC-1 cell line with 10 µM ibrutinib (A,C) or 10 µM idelalisib (B,D) induced by OFA (A,B) or OBZ (C,D)